Trial Profile
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Eflornithine (Primary) ; Sulindac
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PACES
- 04 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 28 Jun 2023 According to a Panbela Therapeutics media release, trial passed a single planned futility analysis and will continue as planned.
- 25 Apr 2022 Planned End Date changed from 1 Jul 2029 to 1 Feb 2032.